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The M protein protruding from the surface of group A streptococci is the
major virulence factor of these organisms. Only antibodies against M protein
opsonize the bacteria and protect mice against challenge infections (1). Recently,
we discovered that M proteins from certain serotypes of group A streptococci
contain epitopes that crossreact with human cardiac sarcolemma (2, 3) and
myosin (4). This has hampered efforts to develop M protein vaccines that would
prevent the streptococcal infections that can trigger acute rheumatic fever and
rheumatic heart disease, mainly because of the fear that the tissue-crossreactive
epitopes within the vaccine preparations may cause, rather than prevent, rheu-
matic heart disease. This has lead to efforts to fragment M protein molecules, in
an attempt to identify protective as opposed to tissue-crossreactive epitopes. In
previous studies (5-7), we showed that synthetic peptide copies ofthe N-terminal
regionsofseveral Mprotein moleculeswere immunogenicandevoked protective,
but not heart-crossreactive antibodies. We now report that another peptide,
SM5(84-116) of type 5 M protein, contains the majority ofmyosin-crossreactive
epitopes of the pepsin-extracted M protein.
Materials and Methods
Extraction and Purification of M Protein.
￿
M protein was purified from limited peptic
digests of type 5 group A streptococci as previously described (8-10). The purified
protein, designated pep M5, was judged to be homogeneous by SDS-PAGE and N-
terminal sequence analysis (9).
Computer Analyses of Protein Sequences.
￿
The amino acid sequence of pep M5 (11, 12)
was compared to published sequences ofthe heavy chain of myosin from nematode (13),
rabbit skeletal (14),and rabbit ventricular(15)muscle usingthesequence analysisprogram
(International Biotechnologies, Inc., New Haven, CT) developed byJim Pustell (16). The
parameters selected were: range = 1, scale = 1, hash = 1, jump = 1, step = 1, and
minimum value plotted = 60.
Chemical Synthesis ofPeptides.
￿
Polypeptide copies spanning theentire pep M5 molecule
(11, 12) were synthesized by an automated peptide synthesizer (Beckman Instruments,
Fullerton, CA)bya solid-phase method, as previously described(6, 7). The peptides were
purified by HPLC and their compositions and sequences were confirmed by quantitative
amino acidanalysisandautomated Edmandegradation,respectively(5, 6,9). The peptides
synthesized for this study are designated SM5(28-54)C, SM5(55-84)C, SM5(84-116)C,
SM5(93-116)C, SM5(101-116)C, SM5(117-146)C, SM5(134-163)C, and SM5(164-197)C.
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An additional peptide, SM5(1-35), was synthesized for a previous study (7), and was also
used in these experiments.
Conjugation ofSM5(84-116)C.
￿
SM5(84-116)C was conjugated to KLH using succinim-
idyl 4-(N-maleimido-methyl) cyclohexane-l-carboxylate (Pierce Chemical Co ., Rockford,
IL) as previously described (7).
Immunization ofRabbits.
￿
New Zealand White rabbits were injected with 300 hg ofpep
M5 emulsified in CFA (3, 9). Blood was obtained before the initial injection and at 2-wk
intervals thereafter. At 4 and 10 wk, the animals were given 300-Ag booster injections in
PBS. Rabbit antisera against SM5(84-116)C-KLH were similarly prepared using 100 Ug
of the conjugate for each dose (7).
Detection ofMyosin-crossreactiveAntibodies.
￿
Sera were tested for the presence ofmyosin-
crossreactive antibodies by ELISA, using purified rabbit muscle myosin (Sigma Chemical
Co., St. Louis, MO) as the solid-phase antigen (4). Myosin-crossreactive epitopes were
detected by ELISA inhibition assays, which were performed by incubating a constant
dilution of antiserum with increasing concentrations of synthetic peptides, pep M5 or
myosin, as soluble inhibitors (4).
Western immunoblots were performed as previously described (3, 4) using SDS-
extracted myocardial proteins from human heart tissue. In immunoblot inhibition exper-
iments, the diluted antisera were first incubated with synthetic peptides or pep M5 before
adding the nitrocellulose strips (4).
Results and Discussion
Previous studies have shown that pep M5 shares epitopes with the heavy chain
of myosin (4, 17), and that streptococcal M proteins and the rod region of myosin
both have primary structures that are characteristic of a-helical coiled-coil
molecules (18). Therefore, in an attempt to identify the primary structures of
pep M5 that might contain myosin-crossreactive epitopes, a computer-assisted
comparison of the amino acid sequences of both molecules was performed (16).
Although there was a significant number of regions showing primary structural
homology between pep M5 and myosin, ranging up to four amino acids in length,
there was no single region ofpep M5 that contained a majority of the homologous
primary structures (J . B. Dale and E. H. Beachey, manuscript in preparation).
For this reason, we elected to synthesize peptides spanning the entire pep M5
molecule, which were used in the following studies.
To localize the myosin-crossreactive epitopes of pep M5, ELISA inhibition
experiments were performed using the synthetic peptides (see Materials and
Methods) as soluble inhibitors of myosin-crossreactive antibodies evoked by pep
M5 (Fig. 1). Only SM5(84-116)C inhibited pep M5 antibody binding to myosin.
This peptide inhibited ELISA by 75%, as compared to 100% inhibition by pep
M5, the immunogen, and 95% by myosin, the ELISA antigen . None of the
remaining synthetic peptides inhibited the binding of antibodies to myosin.
Because most of the myosin-crossreactive antibodies appeared to be binding to
epitopes located in SM5(84-116)C, we also tested the subpeptides SM5(93-116)C
and SM5(101-116)C for their ability to inhibit the ELISA reaction. Neither of
these peptides inhibited the binding of myosin-crossreactive antibodies (Fig. 1),
indicating either that the majority of crossreactive antibodies were recognizing
epitopes located between amino acids 84-93, or that the subpeptides were not
ofsufficient length to retain the conformation required for antibody recognition.
The ELISA inhibition experiments were performed with one of three pep M5
antisera, all of which have previously been shown (4) to contain myosin-cross-DALE AND BEACHEY
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FIGURE 1 .
￿
ELISA inhibition of pep M5 myosin-crossreactive antibodies by SM5(84-116)C.
A constant dilution of anti-pep M5 was incubated with increasing concentrations of either
SM5(84-116)C (0), pep M5 (0), or myosin (0) as soluble inhibitors of antibody binding to
myosin, which was the solid-phase antigen. Additional peptides tested (0) were SM5(1-35),
SM5(28-54)C, SM5(55-84)C, SM5(117-146)C, SM5(134-163)C, SM5(164-197)C, SM5(93-
116)C, and SM5(101-116)C. The highest concentration of synthetic peptides was 40 nM, and
the highest concentrations of myosin and pep M5 were 10 kg/ml.
reactive antibodies. To show that the immunogenicity of the crossreactive
epitopes within the 84-116 region of pep M5 was not related to individual
variations in immune responses, inhibition experiments were also performed
using the remaining antisera. In each case, SM5(84-116)C was the only synthetic
peptide that inhibited the myosin crossreactions, and the patterns of inhibition
were similar to that shown in Fig. I.
The results obtained by ELISA inhibition tests were confirmed by Western
immunoblots using myocardial proteins extracted in SDS from whole human
heart tissue (Fig. 2). SM5(84-116)C almost totally blocked the reaction of pep
M5 antibodies with a protein corresponding to the M, of the heavy chain of
myosin (Fig. 2D). TheN-terminal peptide SM5(1-35) showed no visibleinhibition
(Fig. 2E), nor did the remaining synthetic peptides (data not shown).
To test the immunogenicity of the myosin-crossreactive epitopes within
SM5(84-116)C, three rabbits were immunized with the synthetic peptide conju-
gated to KLH. Two of the animals developed antibodies crossreactive with
myosin, with titers of 200 and 400, respectively, while the preimmune sera all
had titers <100. Thus, the myosin-crossreactive epitopes retained partial immu-
nogenicity; the titers ofthe crossreactive antibodies were significantly lower than
those previously reported (4) after immunization with pep M5, indicating dis-
crepancies between the immunogenicity and antigenicity of the epitopes within
the synthetic peptide.
Taken together, these results suggest that the majority of the myosin-cross-
reactive antibodies evoked by pep M5 are directed against epitopes that are
located within a limited region of the molecule . We have previously shown (5-
7) that synthetic peptide copies ofthe N-terminal region of several serotypes of
M protein contain protective but not tissue-crossreactive epitopes (5-7). There-
fore, it appears that, in some cases, type-specific and heart-crossreactive epitopes1788
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FIGURE 2 .
￿
Western immunoblot inhibition of pep M5 myosin-crossreactive antibodies . SDS-
extracted human myocardial proteins were electrophoresed under reducing conditions on an
SDS-polyacrylamide continuous gradient gel, rangingfrom 7.5 to 15% . Multiple protein bands
were observed on the stained gel (A) . Immunoblot analyses revealed that the pep M5 immune
serum reacted strongly with a protein band of 230,000 M, (B), corresponding to the heavy
chain ofmyosin (4). The myosin-crossreactive antibodies were totally inhibited by pepM5 (C),
almost totally inhibited by SM5(84-I 16)C (D), and not inhibited at all by SM5(1-35) (E), or
any ofthe remaining SM5 peptides (data not shown) . M, X 10-s are shown at left .
of M protein are located within different primary structures, which may be
identified by using synthetic peptide fragments of the native molecule . The
finding that primary structural homologies between pep M5 and myosin were
present throughout the M protein molecule yet SM5(84-116)C was the only
peptide that inhibited myosin antibodies suggests that the crossreactive epitopes
within the 84-116 region may be immunodominant when presented to the
immune system in the context of the entire polypeptide fragment . It is possible,
therefore, that additional myosin-crossreactive epitopes exist within the primary
structure ofpepM5 that are not detected by any of the pep M5 antisera tested .
It is of interest to note that the myosin-crossreactive antisera used in this study
were raised against a pep M5 fragment from one strain of type 5 streptococci
(Manfredo) (3, 4, 12), while the synthetic peptides [except SM5(1-35)] were
synthesized according to the primary structure of pep M5 extracted from a
different strain (11788) (11) . The pep M5 from strain 11788 totally inhibited the
myosin-crossreactive antibodies evoked by pep M5 from strain Manfredo, as
determined by ELISA and Western blot inhibition experiments (data not shown) .
Thus, the myosin-crossreactive epitopes appear to be conserved from one strainDALE AND BEACHEY
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to another, and the inability of SM5(84-116)C to totally inhibit the myosin
antibodies is probably not due to differences in immunological crossreactivity
within this region ofpep M5 extracted from the two strains. Therefore, our data
do not rule out the presence of additional myosin-crossreactive epitopes within
pep M5 that may not beadequatelyrepresented by theseries ofsynthetic peptides
tested.
Although SM5(84-116)C significantly inhibited pep M5 antibody binding to
the heavy chain of myosin in Western immunoblots (see Fig. 2), antibody
reactions with additional polypeptides present in human heart tissue were not
inhibited. In addition, immunofluorescence inhibition tests using frozen sections
of human myocardium showed that SM5(84-116)C only partially inhibited the
binding of pep M5 heart-crossreactive antibodies, whereas pep M5 completely
inhibited the crossreactions (data not shown). We conclude that pep M5 contains
multiple heart-crossreactive epitopes (3), notallofwhich are myosin-crossreactive
(4). Continued efforts to precisely identify the primary structures of M proteins
that are immunologically crossreactive with human tissues should not only allow
the development ofsafe and effective M protein vaccines, but also may provide
insights into the pathogenesis ofrheumatic heart disease.
Summary
Group A streptococcal M proteins contain epitopes that crossreact with sar-
colemmal membrane proteins of human myocardium and myosin. In the present
study, synthetic peptide copies spanning the entire 197-residue pepsin extracted
fragment of type 5 M protein were used to localize the myosin-crossreactive
epitopes of the molecule. Peptide 84-116 inhibited by 75% the binding of
myosin-crossreactive antibodies evoked by pep M5, as determined by ELISA.
Immunoblot inhibition studies confirmed that peptide 84-116 almost totally
inhibited the binding ofpep M5 antibodies to the heavy chain of human cardiac
myosin. None ofthe remainingsyntheticpeptides, including peptide 1-35, which
contains protective epitopes, inhibited antibodies binding to myosin. Two of
three rabbits immunized with peptide 84-116 developed low but significant
levels of antibodies crossreactive with myosin . Identification of the primary
structurescontainingtissue-crossreactive as opposedtoprotective epitopesshould
not only allow the development of safe and effective M protein vaccines, but
may also provide insights into the pathogenesis of rheumatic heart disease.
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